Physician profile
Karlee Muller
NPI 1255838991
$1,752.13
in general payments reported to CMS, 2019-2025
17 companies · $513 in 2025
The $513 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $37.43 · 2021: $167 · 2022: $186 · 2023: $472 · 2024: $180 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $389.31 | 2019-2025 | Cequa |
| Alcon Vision LLC | $242.65 | 2021-2025 | Simbrinza, Rhopressa, Rocklatan |
| Oyster Point Pharma, INC. | $237.21 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $235.48 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $173.98 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $72.02 | 2019-2021 | |
| Sight Sciences, INC. | $61.16 | 2020-2022 | |
| Allergan, INC. | $54.76 | 2021 | |
| Visioneering Technologies, INC. | $47.83 | 2019 | |
| Rxsight INC | $46.88 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $44.81 | 2022-2023 | |
| Johnson & Johnson Vision Care, INC. | $42.05 | 2019-2023 | Acuvue |
| Abbvie INC. | $28.74 | 2024 | |
| Coopervision INC. | $23.44 | 2023 | Myday Contact Lens |
| Dompe US, INC. | $23.20 | 2025 | Oxervate |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $16.23 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karlee Muller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.